末梢動脈疾患に対する新しい直接血液灌流(DHP)治療(<特集>アフェレシス療法における新しいmodality)

概要

論文の詳細を見る
LDL-apheresis (LDL-A) therapy has an apparent clinical effect in improving peripheral arterial disease (PAD). However, the modern system and process of LDL-A is very complicated because 2 steps (plasma separation and treatment of separated plasma) are necessary. Recently, a new direct hemoperfusion (DHP) column for the treatment of PAD was developed. The column is filled with cellulose beads immobilized with dextran sulfate and L-tryptophan, which adsorb LDL cholesterol and fibrinogen by electronic and chemical affinity. Using this new DHP column, a multicenter clinical trial was performed in Japan for evaluating the efficacy and safety of DHP therapy for 52 patients with PAD (Fontaine II-IV). The overall efficacy and safety of DHP apheresis for PAD was 67.3% and 94.9% respectively. We treated 9 patients with PAD using this DHP system (2 hours per session and 10-12 sessions in each patient). A clinical improvement was achieved in 8 out of 9 patients. Along with its clinical effects, skin perfusion pressure (SPP) improved from 28.2±17.4mmHg to 39.2±30.8mmHg, and the ankle-brachial pressure index increased from 0.80±0.22 to 0.91±0.27. The new DHP system is very simple and is effective for patients with PAD.
日本アフェレシス学会の論文
2009-10-31